Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | CAR-T for elderly DLBCL

Frederick Locke • 2 Jun 2019
ASCO 2019
Diffuse Large B-Cell Lymphoma Axicabtagene ciloleucel
ZUMA-1

Frederick Locke, MD, of the Moffitt Cancer Center, Tampa, FL, discusses the treatment of elderly diffuse large B-cell lymphoma (DLBCL) with axicabtagene ciloleucel at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Frederick Locke

CAR T-cell durability in LBCL: antigen presentation, immune engagement, and HLA loss
1:42
CAR T-cell durability in LBCL: antigen presentation, immune engagement, and HLA loss
Frederick Locke • 7 Dec 2025
The survival impact of increasing access to CAR T-cell therapy for R/R DLBCL: an analysis in the US
1:32
The survival impact of increasing access to CAR T-cell therapy for R/R DLBCL: an analysis in the US
Frederick Locke • 7 Dec 2025
Immune exhaustion impacts CAR T-cell efficacy in Richter’s transformation
1:18
Immune exhaustion impacts CAR T-cell efficacy in Richter’s transformation
Frederick Locke • 7 Dec 2025
Integrating autoimmune diseases into cellular therapy centers
26:06
Integrating autoimmune diseases into cellular therapy centers
David Miklos et al. • 12 Apr 2025

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
Community-based management of CAR-T and bispecific antibody-related CRS in B-cell lymphoma
2:17
Community-based management of CAR-T and bispecific antibody-related CRS in B-cell lymphoma
Michael Jain • 11 Sep 2026
Optimizing post-CAR-T monitoring and community delivery after liso-cel
1:04
Optimizing post-CAR-T monitoring and community delivery after liso-cel
Bradley Hunter • 21 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals